Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 8Lymphoid 5Myeloid 2Sarcoma 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2

Interventions

fludarabine 63Cyclophosphamide 63venetoclax 58Azacitidine 54fludarabine phosphate 50Specimen Handling 44ruxolitinib 40Whole-Body Irradiation 40Mycophenolic Acid 37Tacrolimus 35Melphalan 32Busulfan 32Biopsy 32Cytarabine 31Decitabine 28Stem Cell Transplantation 27Granulocyte Colony-Stimulating Factor 21Injections 20asciminib 19decitabine and cedazuridine drug combination 18Sirolimus 18Peripheral Blood Stem Cell Transplantation 18Thiotepa 17Filgrastim 17nilotinib 16X-Rays 14Methotrexate 14Imatinib Mesylate 14Cyclosporine 14Magnetic Resonance Spectroscopy 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
olverembatinib × Myeloid × 1 year × Clear all
NCT06817720 2026-05-20

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07383298 2026-02-03

Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase

Peking University People's Hospital

Enrolling by invitation
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡